Editorial Volume 11, Issue 20 pp 8743—8744

CD38-NAD+-Sirt1 axis in T cell immunotherapy

Figure 1. The summary of observation illustrating the unique immunometabolic phenotype of ex vivo generated hybrid TH1/TH17 cells that exhibit reduced CD38 expression, high NAD and long-term tumor control upon adoptive transfer.